Navigation Links
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Date:12/20/2007

REDWOOD CITY, Calif., Dec. 20 /PRNewswire/ -- Pearl Therapeutics, Inc., a biopharmaceutical company developing treatments for major respiratory diseases, today announced the appointment of Colin Reisner, MD, FCCP, FAAAAI to the position of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs, and Michael Golden to the position of Vice President, Regulatory Affairs and Quality.

"We are delighted to welcome Colin and Michael as we continue to build our team with experts in the development of respiratory products," said Adrian Smith, President, Pearl Therapeutics, Inc. "Both Colin and Michael have proven records of success in the pharmaceutical industry and are innovative leaders who have designed and managed the clinical and CMC development programs of many marketed products, from pre-clinical through NDA filing and commercialization."

Dr. Reisner joins Pearl from Novartis Pharmaceuticals where he was Executive Director and former Disease Area Section Head for Global Respiratory Development, a position focused on both clinical development leadership and shaping Novartis' global strategy for respiratory products. He led the clinical development activities of several programs in asthma, COPD, and cystic fibrosis, assessing single and combination therapies across a wide range of delivery systems and dosage forms. Earlier at Novartis, Dr. Reisner served as the Global Brand Medical Director for Xolair(R), the first biologic agent approved for asthma. In this capacity, he oversaw all clinical activities ranging from design and implementation of the pediatric development program to the European approval for the treatment of severe persistent allergic asthma.

Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline, and as the International Project Leader for beta agonists. Dr. Reisner played a diverse and integral role in the development of several key product
'/>"/>

SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ ... help predict the adverse and therapeutic effects of a ... Computational Biology at the Genomics Laboratory, Covance, will discuss ... genomics when used as part of the QC process. ... sets to identify key clinical targets even in complex ...
(Date:5/16/2013)... OH (PRWEB) May 16, 2013 The ... manufactured by Global Cooling, Inc., Athens, OH, USA, won ... 2013 by the International Society for Biological and Environmental ... The award, given to one product annually, recognizes the ... efficient ultra-low temperature freezer. The award was presented ...
(Date:5/16/2013)... Mass. (PRWEB) May 16, 2013 Cambridge ... Summit from August 19-23, 2013 at the Renaissance Waterfront ... the Summit provide a close-up look at the current ... and ensuring bottom-line quality. Leaders in the field ... ways to produce biopharmaceuticals with greater specificity and efficiency. ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2
... , SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ... 2009. Revenue for the third quarter of 2009 was $25,000 ... Revenue for the nine months ended September 30, 2009 was ... 30, 2008. , Dendreon,s total operating expenses for the ...
... MADRID, November 11 Cellerix, a ... today announced the successful first closing of its financing ... current,shareholders and a select group of new investors. Cellerix ... , This round was led ...
... AMSTERDAM, November 11 Amsterdam ... human gene therapy,announced today that it has successfully treated ... proprietary gene therapy. The proof of,concept studies were performed ... of Rome, La Sapienza, Italy) and demonstrated,effectiveness in the ...
Cached Biology Technology:Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6Cellerix Raises EUR27 Million in a First Closing 2AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... calculated that the bite force of the great white,s ... (also known as Big Tooth) is the highest ... carnivore ever to have existed. Shark researchers from ... Department of Primary Industries Fisheries (Australia) and University of ...
... Fruit and Vegetable Consumption Is Low among Black Men ... fruits and vegetables, daily consumption of these foods among ... researchers at Columbia and Temple universities, the University of ... study of 490 American and foreign-born black men between ...
... - JDRF said today that it has recognized the work ... the pace of science in understanding the autoimmune attack that ... severe complications of this chronic and life-threatening disease. ... Dr. Jeffrey A. Bluestone, Director of the Diabetes Center at ...
Cached Biology News:Great white's mighty bite revealed 2Highlights from the August 2008 Journal of the American Dietetic Association 2JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3
...
... Grace's medium was originally formulated to support ... Australian emperor gum moth,Antherea eucalypti. The medium ... more closely resembleAnthereahemolymph. The cell lines established ... first continuous lines developed. The basal medium, ...
... and Digital Orbital Shaker. Our durable, rugged VSOS-4 ... every day use even easier. This advanced Orbital ... 4 different programs. Its easy recall function allows ... VSOS-4P has a pulse operation for a short ...
... The MONOLIGHT 3096 Microplate Luminometer ... chemi- and bioluminescence and for,all measurements ... microplates,i.e. for reactions where the light ... of time, as well as for ...
Biology Products: